# Cannabis Terpenes When You Inhale Them: One Controlled Human Trial, a Large Preclinical Literature, and a Dose Gap Nobody Mentions > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/inhaled-cannabis-terpenes-evidence/ > **Published:** 2026-09-04T22:53:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:47-04:00 > **Clinical Summary:** Inhaled cannabis terpenes have one controlled human trial behind them. It found d-limonene blunted THC anxiety at 15 mg, a dose flower does not deliver. --- CED Clinical Relevance #71Strong Clinical RelevanceTerpene claims drive product selection at dispensary counters more than almost anything else, and they are the least supported claims in cannabis retail. Knowing which terpene effects have been measured in a person, and at what dose, is the difference between an informed choice and a purchase made on a story. Terpenes are the most confidently described and least studied part of the cannabis plant. One controlled human trial has tested an inhaled cannabis terpene against placebo and found a narrow, real effect at a dose that is unlikely to come out of a flower. Nearly everything else attributed to terpenes comes from cell assays, mouse behavior, or aromatherapy research on unrelated plants. Clinical Insight | CED Clinic In the one randomized controlled human trial of an inhaled cannabis terpene, published in *Drug and Alcohol Dependence* in 2024, vaporized d-limonene given alone at 1 mg or 5 mg was indistinguishable from placebo on every pharmacodynamic outcome measured. Combined with 30 mg of vaporized THC, 15 mg of d-limonene significantly reduced ratings of anxious or nervous and of paranoid compared with 30 mg THC alone, and changed nothing else. That is a real finding and a narrow one. It supports a specific interaction at a specific dose, and it is currently the entire human evidence base for inhaled cannabis terpenes. TerpenesEntourage EffectD-LimoneneEvidence AppraisalInhalation AudiencePatients, caregivers, and cliniciansPrimary TopicHuman and preclinical evidence for the effects of inhaled cannabis terpenes and the entourage effectSource[Read the full source](https://doi.org/10.1016/j.drugalcdep.2024.111267) Why This Matters Patients choose products by terpene profile because dispensaries present terpene profiles as functional information. Myrcene for sedation, limonene for mood, pinene for focus. Those assignments circulate as established pharmacology and were, in almost every case, never tested in a human being. There is a real signal in this area worth protecting from the noise around it. A terpene that reliably blunted THC-induced anxiety would meaningfully widen the therapeutic window of THC, and one trial suggests d-limonene may do that. Overclaiming for every terpene makes the one credible finding harder to hear. The One Human Trial, and Exactly What It Found Tory Spindle and colleagues at Johns Hopkins ran the study the field had been asserting the results of for twenty years. Twenty healthy adults who used cannabis intermittently completed nine double-blind outpatient sessions, inhaling vaporized THC alone at 15 mg or 30 mg, d-limonene alone at 1 mg or 5 mg, the same doses of both together, or placebo. Twelve of them completed a tenth session at 30 mg THC plus 15 mg d-limonene. Outcomes included subjective drug effects, cognitive and psychomotor performance, vital signs, and plasma concentrations of both compounds. D-limonene administered alone did not differ from placebo on any outcome. Whatever terpenes do, at these doses and by this route, d-limonene by itself did not produce a measurable effect in people. THC alone produced the expected profile. Ratings of anxiety-like effects fell as the d-limonene dose rose, and at 30 mg THC with 15 mg d-limonene, ratings of anxious or nervous and of paranoid were significantly lower than with 30 mg THC alone. No other pharmacodynamic outcome changed. Cognitive performance, heart rate, and the overall subjective intensity of the THC experience were unaffected, and d-limonene did not alter THC pharmacokinetics, so the mechanism is not a change in THC exposure. The authors’ framing is the right one: d-limonene selectively attenuated THC-induced anxiogenic effects and could increase the therapeutic index of THC. That is a hypothesis-generating result in 20 people, and it is the strongest thing anyone can honestly say about an inhaled cannabis terpene. The Dose Gap Between the Trial and the Flower The effect in that trial required 15 mg of purified d-limonene delivered by vaporizer alongside 30 mg of THC. The 1 mg and 5 mg doses produced qualitative trends and did not reach the same threshold. The active ratio was one part limonene to two parts THC by weight. That ratio is the part of the study nobody quotes. The investigators did not use a cannabis chemovar rich in limonene. They vaporized isolated d-limonene separately, because that was the only way to control the dose. Whether any commercially available flower delivers 15 mg of inhaled d-limonene is not a question the trial addressed, and it is not a question the published literature answers. No indexed study has measured the milligram quantity of any terpene actually delivered to a person by smoking or vaporizing a given weight of cannabis. Terpenes are volatile, a substantial fraction is lost to evaporation during drying, curing, and storage, and combustion temperatures exceed the boiling points of every monoterpene in the plant. The practical consequence is that a patient selecting flower by a limonene percentage on a certificate of analysis is not reproducing the trial. They may be getting a fraction of the dose, and nobody has published the number that would tell them. What the Preclinical Work Shows, and What It Does Not The terpene literature below the human level is large and genuinely interesting, and it points in more than one direction. Marina Santiago and colleagues at Macquarie University tested the proposition directly in vitro. Six of the most common cannabis terpenoids, alpha-pinene, beta-pinene, beta-caryophyllene, linalool, limonene, and beta-myrcene, at concentrations up to 30 to 100 micromolar, did not activate CB1 or CB2 receptors, did not modulate the response to a maximally effective synthetic cannabinoid, did not change the hyperpolarization produced by 10 micromolar THC, and did not affect receptor desensitization over 30 minutes. Their title states the conclusion: absence of entourage. If a terpene and cannabinoid interaction exists, it is not happening at the cannabinoid receptors. Justin LaVigne and colleagues at the University of Arizona reached a different conclusion using different methods. In *Scientific Reports* in 2021, alpha-humulene, geraniol, linalool, and beta-pinene produced cannabinoid tetrad behaviors in mice, effects that were partially blocked by cannabinoid or adenosine receptor antagonists, and these behavioral effects were selectively additive with a synthetic cannabinoid agonist. In their assays all four terpenes activated CB1. Mouse behavior and a cell line are not the same preparation, and the discrepancy has not been resolved. Beta-caryophyllene is the one compound with well-established receptor pharmacology. Jurg Gertsch and colleagues showed in *Proceedings of the National Academy of Sciences* in 2008 that it binds CB2 selectively with a Ki of 155 nanomolar, functions as a CB2 agonist, inhibits lipopolysaccharide-induced cytokine expression in human monocytes, and reduces carrageenan-induced inflammation in wild-type mice but not in mice lacking CB2 receptors. That is a clean mechanistic demonstration. It was done with oral dosing at 5 mg per kilogram in mice, and it says nothing about what inhaling beta-caryophyllene does to a person. The Claims With No Human Evidence At All Several terpene claims are repeated so consistently that they have acquired the sound of established fact. They are not. Myrcene is described as increasing blood brain barrier permeability and thereby speeding or intensifying cannabinoid effects. A PubMed search for myrcene and blood brain barrier returns nothing. There is no indexed study supporting this claim, in humans or otherwise, and it appears to have entered circulation through repetition rather than through data. There is also no indexed randomized human trial of myrcene as a sedative. Alpha-pinene is described as counteracting THC-induced short-term memory impairment. No published human trial has tested this. The Spindle trial is the only controlled human study of a cannabis terpene administered with THC, and the terpene it tested was d-limonene, and the outcome that changed was anxiety rather than memory. Linalool is described as sedative on the strength of lavender research. The human inhalation literature on linalool is aromatherapy research using lavender essential oil, not studies of the terpene isolated from cannabis at cannabis-relevant doses. Whether those findings transfer is an assumption, not a result. None of this means the claims are false. It means they are untested, and a physician’s site should describe them that way. The correct statement about most cannabis terpenes is that we know what they smell like, we know what they do to receptors in a dish or behavior in a mouse, and we do not know what they do to a person who inhales them. How to Use Terpene Information Without Overreading It None of this argues for ignoring terpene profiles. It argues for using them as what they reliably are: a chemical fingerprint of a specific plant batch. Terpene profiles are the most practical tool available for reproducing a product that worked. Two batches sold under the same cultivar name can differ substantially in chemistry, and the terpene profile on a certificate of analysis is the closest thing to a batch signature a patient can read. If a particular flower helped, matching its full terpene and cannabinoid profile is a more reliable way to repeat the result than matching the name on the jar. The one claim with human trial support is worth acting on cautiously. If THC-induced anxiety is the limiting problem for a patient, a limonene-dominant product is a reasonable thing to try, with the honest caveat that the trial dose was 15 mg of purified terpene and the flower may not deliver it. Beyond that, the most useful guidance is to treat subjective response as the primary data. A patient who notices that one chemovar reliably helps and another reliably does not has generated more relevant evidence about their own physiology than any current terpene claim can supply. Recording the profile that worked is worth more than a theory about why. Evidence Snapshot: Inhaled TerpenesAnchor TrialVaporized D-limonene selectively mitigates the acute anxiogenic effects of delta-9-tetrahydrocannabinol in healthy adults who intermittently use cannabisDesignDouble-blind, placebo-controlled, within-subject outpatient study; nine sessions per participant, plus a tenth for a subsetParticipants20 healthy adults who used cannabis intermittently; 12 completed the highest combination sessionDoses TestedVaporized THC 15 mg or 30 mg; d-limonene 1 mg, 5 mg, or 15 mg; combinations; placeboTerpene AloneD-limonene alone did not differ from placebo on any pharmacodynamic outcomePositive Finding30 mg THC plus 15 mg d-limonene significantly reduced ratings of anxious or nervous and of paranoid versus 30 mg THC aloneMechanism NoteD-limonene did not alter THC pharmacokinetics, so the effect is not explained by changed THC exposureJournalDrug and Alcohol Dependence, 2024;257:111267PMID / DOI38498958 / 10.1016/j.drugalcdep.2024.111267Contradicting In Vitro DataSix common terpenoids did not activate or modulate CB1 or CB2 signaling at up to 100 micromolar (Santiago 2019, Cannabis Cannabinoid Res 4(3):165-176, PMID 31559333)Supporting Animal DataAlpha-humulene, geraniol, linalool, and beta-pinene produced cannabinoid tetrad behaviors in mice and were additive with a synthetic agonist (LaVigne 2021, Sci Rep 11(1):8232, PMID 33859287) How Strong Is This Evidence? The human evidence tier here contains exactly one study, and it is a good one: randomized, double-blind, placebo-controlled, within-subject, with plasma concentrations measured for both compounds and a dose range that allowed a gradient to be observed. Its limitations are sample size, a single terpene, a single route, acute exposure, and healthy volunteers rather than patients. Below that tier the evidence is abundant and conflicting. One well-conducted receptor study found no terpene modulation of cannabinoid signaling at all, and one well-conducted mouse study found cannabimimetic behavior and additivity. Both cannot be describing the same underlying biology in the same way, and neither describes a human being inhaling flower. Where This Paper Deserves Skepticism Twenty participants, one terpene, and an acute laboratory session is a starting point rather than a conclusion. The anxiety finding rests on self-reported visual analogue ratings, which are the outcome most vulnerable to expectancy in a study where participants can tell they have received THC. The absence of any effect from d-limonene given alone is worth sitting with. It means the compound marketed for mood elevation produced nothing detectable in healthy adults at 1 and 5 mg by inhalation. Whatever it contributes, it appears to require the presence of THC. The entourage effect as commonly described, that whole plant preparations are greater than the sum of their parts, is a hypothesis that the best-controlled receptor study to date failed to support. One positive human interaction with one terpene at one dose does not validate the general claim. What This Paper Does Not Show No human study shows that myrcene causes sedation, that pinene protects memory, that linalool inhaled from cannabis relieves anxiety, or that any terpene amplifies analgesia in people. No indexed study supports the claim that myrcene increases blood brain barrier permeability to cannabinoids. No published study quantifies how many milligrams of any terpene a person actually inhales from smoking or vaporizing a given weight of cannabis flower, which means the dose relationship between the one positive trial and any retail product is unknown. How This Fits With the Broader Clinical Conversation Terpenes occupy a strange position in [cannabis medicine](https://cedclinic.com/cbd-gummies-smoking-cessation/). They are the most sensorially obvious part of the plant, which makes their effects feel self-evident, and they are the least studied part, which means almost nothing about them has been demonstrated. That combination is ideal conditions for confident misinformation. The same pattern appears with the minor cannabinoids, where compounds reach retail shelves with specific functional claims years before anyone gives them to a person in a controlled setting. The correct response in both cases is the same: sort the claims by the tier of evidence behind them and say which tier each one sits in. There is a constructive version of the terpene hypothesis that the d-limonene trial supports. Rather than asking what each terpene does on its own, ask which plant constituents modify the effects of THC, and in which direction. A compound that reduces THC-induced anxiety without reducing its other effects would be genuinely useful. That is a researchable question and it now has one positive answer. Dr. Caplan’s Take Terpenes are the subject I get asked about most and can say the least about with confidence. Patients arrive with a printed chart assigning a mood and a medical use to each terpene, and the chart is almost entirely invention. I try not to be dismissive about it, because the underlying instinct is correct: the same THC percentage does behave differently across products, and patients notice that before researchers explain it. What I have found useful in practice is treating the terpene profile as a batch fingerprint rather than a prescription. When a patient tells me a particular flower worked, I want the full certificate of analysis, not the strain name, because the name will not reproduce and the chemistry might. The limonene and anxiety result is the one I have changed my practice around, modestly. For a patient whose limiting problem with THC is anxiety, a limonene-dominant product is worth trying. I tell them the study used a purified dose delivered by vaporizer and that we do not know whether their flower gets close to it. That is the honest version, and in my experience patients would rather have it than a chart. Clinical Bottom Line One randomized controlled human trial has tested an inhaled cannabis terpene. It found that 15 mg of vaporized d-limonene reduced THC-induced anxiety and paranoia without changing anything else, and that d-limonene alone did nothing at all. Every other functional terpene claim in common circulation rests on cell assays, mouse studies, or aromatherapy research on other plants. Use terpene profiles to reproduce products that worked, treat the limonene finding as a reasonable thing to try for THC-related anxiety, and treat the rest as untested. What a Careful Reader Should Take Away Carry forward the distinction between a mechanism and an outcome. Beta-caryophyllene really does activate CB2 receptors, and no one has measured what that means for a person inhaling it. D-limonene really did blunt THC anxiety in a controlled trial, at a dose that came from a vaporizer rather than a plant. Everything else on the standard terpene chart belongs in the untested column until someone runs the study. Evidence Interpretation Guide Table of Contents - [How to sort terpene claims by the tier of evidence behind them](#How_to_sort_terpene_claims_by_the_tier_of_evidence_behind_them) - [Inhaled Cannabis Terpenes, Seen From Eight Angles](#Inhaled_Cannabis_Terpenes_Seen_From_Eight_Angles)[The terpene chart is mostly not evidence](#The_terpene_chart_is_mostly_not_evidence) - [Use the certificate of analysis as a batch identifier](#Use_the_certificate_of_analysis_as_a_batch_identifier) - [One positive trial does not validate the entourage effect](#One_positive_trial_does_not_validate_the_entourage_effect) - [The dose is the weak link](#The_dose_is_the_weak_link) - [Two decades of assertion, one experiment](#Two_decades_of_assertion_one_experiment) - [What to try if THC anxiety is the problem](#What_to_try_if_THC_anxiety_is_the_problem) - [Three studies that would settle most of this](#Three_studies_that_would_settle_most_of_this) - [Labels imply pharmacology that does not exist](#Labels_imply_pharmacology_that_does_not_exist) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to sort terpene claims by the tier of evidence behind them The Research QuestionWhat effects have inhaled cannabis terpenes been shown to produce in controlled human studies, and at what doses?The Patient QuestionShould I be choosing [cannabis products](https://cedclinic.com/cbd-gummies-daily-use-evidence-men/) by their terpene profile, and do the effects on the chart actually happen?The Bottom LineOne human trial, one terpene, one effect: 15 mg of vaporized d-limonene reduced THC-induced anxiety. Alone it did nothing. The rest of the terpene chart has not been tested in people. CED Perspective Lens ## Inhaled Cannabis Terpenes, Seen From Eight Angles The most confidently described and least studied constituents of the plant, sorted by what has actually been measured. Lens OverviewA randomized controlled trial found that 15 mg of vaporized d-limonene selectively reduced THC-induced anxiety and paranoia in 20 healthy adults, while d-limonene alone was indistinguishable from placebo. It is the only controlled human study of an inhaled cannabis terpene. #### The terpene chart is mostly not evidence The assignments you see at dispensaries, myrcene for sleep, limonene for mood, pinene for focus, come from tradition and marketing rather than from studies in people. Only one terpene has been tested in a controlled human trial, and the effect it produced was reducing anxiety caused by THC, not producing any effect of its own. That does not mean your experience is imaginary. Different products genuinely feel different, and terpene profiles are part of the chemistry that differs. It means the explanation on the chart has not been verified. Lens takeawayTrust your own response to a specific product more than the function assigned to a terpene on a label. #### Use the certificate of analysis as a batch identifier The most defensible clinical use of terpene data is reproducibility. Cultivar names do not reliably predict chemistry, and a full terpene and cannabinoid profile is the closest thing a patient has to a reproducible product specification. When a patient reports a good response, record the profile rather than the name. That practice is supported regardless of whether any individual terpene turns out to be pharmacologically active. Lens takeawayRecord the chemistry of what worked. The strain name will not reproduce and the profile might. #### One positive trial does not validate the entourage effect The general entourage claim is that whole plant preparations exceed the sum of their parts. The most direct test of that at cannabinoid receptors found no terpene modulation of CB1 or CB2 signaling at concentrations up to 100 micromolar. The d-limonene trial shows one interaction, in one direction, on one outcome, at one dose. Extending that to a general principle about whole plant superiority is precisely the overreach the trial was designed to test rather than assume. Lens takeawayA single specific interaction is not evidence for a general synergy claim. #### The dose is the weak link The effect required 15 mg of purified d-limonene alongside 30 mg of THC. Lower doses produced qualitative trends that did not reach the same threshold. No published study measures how much of any terpene a person actually inhales from a given amount of flower, and combustion temperatures exceed monoterpene boiling points. The gap between the trial dose and the retail product is unquantified, which means nobody can say whether the finding transfers. Lens takeawayA result at 15 mg of purified terpene may or may not be reachable from a plant. That is currently unknown. #### Two decades of assertion, one experiment The entourage concept has circulated in cannabis medicine since the late 1990s and has shaped product development, marketing, and patient expectations throughout. For most of that period it rested on plausible chemistry and clinical impression. The Johns Hopkins trial published in 2024 is the first controlled human test of an inhaled cannabis terpene against placebo. That a foundational idea in the field waited that long for a direct test says a great deal about the state of the evidence base. Lens takeawayA central premise of cannabis product design received its first human test in 2024. #### What to try if THC anxiety is the problem A limonene-dominant product is a reasonable experiment for a patient whose THC use is limited by anxiety, with the explicit caveat that the trial delivered a controlled 15 mg dose of purified terpene by vaporizer. Lowering the THC dose remains the intervention with the clearest evidence behind it for THC-induced anxiety. The terpene approach is an addition to that, not a replacement for it. Lens takeawayLower the THC first. A limonene-forward product is a reasonable second lever, not the first one. #### Three studies that would settle most of this First, a quantification of the milligram terpene dose delivered by combustion and by vaporization at defined temperatures. Without that number, no terpene trial result can be translated into a product recommendation. Second, replication of the d-limonene finding in patients rather than healthy volunteers. Third, the same design applied to myrcene, pinene, and linalool, which are the terpenes carrying the heaviest claims and the least data. Lens takeawayMeasure the delivered dose, replicate in patients, and test the three terpenes everyone already believes in. #### Labels imply pharmacology that does not exist Certificates of analysis report terpene percentages, and retail environments present those percentages as functional guidance. The underlying claim, that a given terpene percentage predicts a given effect, has not been established for any terpene by any route. Reporting chemistry accurately is useful and should continue. Presenting it as a predictor of clinical effect is a marketing practice rather than a scientific one, and the gap between the two is currently large. Lens takeawayTerpene content is legitimate product information. Terpene effect claims on labels are not yet supportable. Related Reading at CED ClinicContinue exploring the evidence[CBG, CBN, CBC, and THCV: Which Cannabinoid Claims Come From Human Studies](https://cedclinic.com/minor-cannabinoids-human-evidence/) The same evidence-tier approach applied to the minor cannabinoids, which follow an almost identical pattern of confident claims and thin trials. [Compare the cannabinoid evidence](https://cedclinic.com/minor-cannabinoids-human-evidence/)[Cannabis Plant Anatomy: What the Microscopy Shows About Where Cannabinoids Come From](https://cedclinic.com/cannabis-plant-anatomy-trichomes-guide/) Where terpenes are produced and stored in the plant, which explains why they are so easily lost before inhalation. [See where terpenes form](https://cedclinic.com/cannabis-plant-anatomy-trichomes-guide/)[Irradiated Cannabis: Radioactivity, Terpenes, and Safety](https://cedclinic.com/irradiated-cannabis-radioactivity-terpenes-and-safety/) How post-harvest processing changes terpene content, and what that means for reproducing a product that worked. [Read about terpene loss](https://cedclinic.com/irradiated-cannabis-radioactivity-terpenes-and-safety/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Do cannabis terpenes actually do anything when inhaled? One controlled human trial has tested this. Vaporized d-limonene given alone at 1 mg or 5 mg was indistinguishable from placebo on every outcome measured in 20 healthy adults. Combined with 30 mg of vaporized THC, 15 mg of d-limonene significantly reduced ratings of anxious or nervous and of paranoid. So the answer is that one terpene has shown one effect, and only in the presence of THC. What is the entourage effect and has it been proven? It is the hypothesis that cannabis constituents work together so the whole plant exceeds the sum of its parts. The most direct receptor test found that six common terpenoids did not activate CB1 or CB2 or modulate THC signaling at concentrations up to 100 micromolar. One human trial found a specific interaction between d-limonene and THC on anxiety. A specific interaction is not the same as a general synergy principle. Does myrcene make you sleepy or increase cannabis absorption? Neither claim has published support. No indexed study links myrcene to blood brain barrier permeability, despite that assertion appearing constantly in cannabis education material, and no randomized human trial has tested myrcene as a sedative. The claim appears to have spread through repetition rather than evidence. That does not make it false, but it is currently untested rather than established. Does pinene protect against THC memory impairment? No human trial has tested this. The only controlled human study of a cannabis terpene given with THC used d-limonene, and the outcome that changed was anxiety rather than memory. Cognitive performance in that trial was unaffected by the terpene. The pinene and memory claim comes from preclinical reasoning and has not been examined in people by any published study. Is beta-caryophyllene a cannabinoid? Functionally, yes. A 2008 study in Proceedings of the National Academy of Sciences showed that beta-caryophyllene binds the CB2 receptor selectively with a Ki of 155 nanomolar, acts as a CB2 agonist, suppresses cytokine expression in human monocytes, and reduces inflammation in wild-type mice but not in mice lacking CB2. That is established mechanism. What inhaling it does in a person has not been studied. How much terpene do you actually inhale from cannabis flower? Nobody has published the number. No indexed study quantifies the milligrams of any terpene delivered to a person by smoking or vaporizing a given weight of flower. Terpenes are volatile and are lost during drying, curing, and storage, and combustion temperatures exceed the boiling points of the monoterpenes in the plant. This gap makes trial doses difficult to translate to products. Should I choose cannabis products by terpene profile? Use terpene profiles as a batch fingerprint rather than as a prediction of effect. Cultivar names do not reliably indicate chemistry, so the full terpene and cannabinoid profile on a certificate of analysis is the most practical way to reproduce a product that worked for you. The functional assignments printed on dispensary charts have not been tested in humans for any terpene except d-limonene. If THC makes me anxious, would a limonene-rich product help? It is a reasonable thing to try and it is not guaranteed. The one supporting trial used 15 mg of purified d-limonene delivered by vaporizer alongside 30 mg of THC, and whether flower delivers a comparable dose is unknown. Lowering the THC dose has clearer evidence behind it for THC-induced anxiety, so that remains the first adjustment rather than the second. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).